These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 28258679)

  • 21. [Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID)].
    Ikama SM; Makani J; Ellenga-Mbolla B; Ondze-Kafata LI; Gombet TR; Kimbally-Kaky G
    Pan Afr Med J; 2017; 27():31. PubMed ID: 28761607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
    Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
    Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
    Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
    Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
    Schinkel AF
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary and secondary prevention of ventricular arrhythmias in dilated cardiomyopathy: nonsustained, sustained, and incessant.
    Meyer C; Schueller P; Rodenbeck A; Hennersdorf M; Merx M; Winter J; Rassaf T; Kelm M; Schauerte P
    Int Heart J; 2009 Nov; 50(6):741-51. PubMed ID: 19952471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy.
    Negishi K; Negishi T; Zardkoohi O; Ching EA; Basu N; Wilkoff BL; Popović ZB; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1153-60. PubMed ID: 26710819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
    Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
    N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of microvolt T-wave alternans testing in scheduling implantable cardioverter-defibrillator placement for the primary prevention of sudden cardiac death in patients with left ventricular dysfunction.
    Daniłowicz-Szymanowicz L; Suchecka J; Zagożdżon P; Szwoch M; Kempa M; Raczak G
    Kardiol Pol; 2015; 73(6):429-36. PubMed ID: 25371309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P; Gadler F; Liv P; Mörner S
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Necessity of an ICD-Therapy in Patients with Indications for Primary Prevention of Sudden Cardiac Death. One Center Experience.
    Postol AS; Neminushchiy NM; Antipov GN; Ivanchenko AV; Lyashenko VV; Vygovsky AB; Shnejder YA
    Kardiologiia; 2021 May; 61(4):24-31. PubMed ID: 33998405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators.
    Watanabe T; Inoue K; Kashiwase K; Mine T; Hirooka K; Shutta R; Mizuno H; Okuyama Y; Sakata Y; Nanto S;
    J Electrocardiol; 2018; 51(6):1111-1115. PubMed ID: 30497740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic therapy in heart failure.
    Eckardt L; Haverkamp W; Breithardt G
    Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
    Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D
    J Am Coll Cardiol; 2018 Oct; 72(14):1653-1676. PubMed ID: 29097297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.